At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events

Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Oct 2, 2015
Amicus Therapeutics to Host FDA Update Conference Call Today

Oct 2, 2015
Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy

View all »Events & Presentations

Oct 2, 2015 at 11:00 AM ET
Amicus Therapeutics FDA Update Conference Call

Sep 30, 2015 at 2:45 PM ET
LEERINK Partners Rare Disease Roundtable

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy